Novel cell related to prostatic cancer lineage plasticity as well as identification method and application thereof
Through WGCNA and single-cell transcriptome analysis, novel cell type LPCs and specific gene markers related to prostate cancer lineage plasticity were identified and verified, which solved the problem of plasticity recognition of prostate cancer lineages and provided a prediction method for prostate cancer progression and prognosis. , providing a new direction for personalized treatment.
Patent Information
- Application Number
- CN202411009479.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Currently, there is a lack of robust methods to identify and evaluate gene markers for the plasticity status of prostate cancer lineages, and it is impossible to identify cell types related to lineage plasticity at single-cell resolution. The impact and application value of the impact on prostate cancer progression and its application value are unknown.
WGCNA analysis was performed based on the PCaProfiler bulk RNA-seq cohort, and the lineage plasticity-related gene signature LPSig of prostate cancer was constructed in combination with the NEPAL model, and AUCell enrichment analysis was performed using single-cell transcriptome maps to further determine the five major epithelial cell types. Novel cells that exhibit low AR activity, enhanced stem cell properties and increased lineage plasticity-related signals were selected to identify their specific gene markers such as HMMR, EZH2 and AURKA.
A highly relevant prostate cancer epithelial cell type LPCs was discovered and verified, providing a new research direction for biomarkers, providing new possibilities for personalized and precise treatment of prostate cancer patients, and the gene marking activity of LPCs is similar to that of prostate gland. Malignant progression of cancer is significantly correlated with adverse prognosis.
Smart Images

Figure CN118910257A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to prostate cancer cell detection technology and biomedical fields, and in particular to a new type of cell associated with prostate cancer lineage plasticity and an identification method and application thereof. Background Art
[0002] Prostate cancer is the most common cancer in men worldwide and the second leading cause of cancer-related death. Although almost all patients with hormone-sensitive prostate cancer (HSPC) have a significant therapeutic response to therapies targeting androgen (AR) receptor signaling, drug resistance is inevitable, and hormone-sensitive prostate cancer often evolves into a more aggressive castration-resistant prostate cancer (CRPC) subtype. Most castration-resistant prostate cancers are still histologically classified as adenocarcinomas (CRPC-Adeno) with reactivated AR signaling pathways. However, with the widespread use of second-generation AR signaling inhibitors (ARSi) such as enzalutamide and abiraterone, approximately 40% of castration-resistant prostate cancers have transformed from an AR-dependent luminal cancer cell state to an alternative lineage program with persistent AR expression but low AR activity, presenting a more aggressive phenotype. These tumors that lose AR dependence can further undergo transdifferentiation, resulting in loss of AR expression without neuroendocrine differentiation.Subsequently, these tumors may undergo neuroendocrine differentiation under specific conditions (such as gene mutations, epigenetic changes, etc.), showing the expression of markers such as CHGA, SYP, ENO2 and NCAM1 (CRPC-NE), and eventually develop into a neuroendocrine prostate cancer (NEPC) subtype with a higher lethality (LABRECQUE MP, COLEMAN IM, BROWN LG, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractorymetastatic castration-resistant prostate cancer[J]. J Clin Invest, 2019, 129(10): 4492-505., MU P, ZHANG Z, BENELLI M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer[J]. Science, 2017, 355(6320): 84-8., ALUMKAL JJ, SUN D, LU E, et al. al. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance [J]. Proc Natl Acad Sci USA, 2020, 117(22):12315-23.).
[0003] Recent evidence suggests that the resistance and development of neuroendocrine prostate cancer is due to a transdifferentiation mechanism called lineage plasticity, which suggests that some AR-positive adenocarcinoma cells in prostate cancer can directly transdifferentiate into a neuroendocrine state after acquiring a stem cell state and become resistant to AR-targeted therapy (YAMADA Y, BELTRANH. Clinical and Biological Features of Neuroendocrine Prostate Cancer[J]. Curr Oncol Rep, 2021, 23(2): 15., MU P, ZHANG Z, BENELLI M, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer[J]. Science, 2017, 355(6320): 84-8., BRADY NJ, BARBIERI C E. JAK inhibition shows two faces in prostate cancer[J]. Nat Cancer, 2022, 3(9): 1021-3., IMAMURA J,GANGULY S,MUSKARAA,et al.Lineage plasticity and treatment resistance inprostate cancer: the intersection of genetics,epigenetics,and evolution[J].Front Endocrinol(Lausanne),2023,14(1191311.).
[0004] However, there is currently a lack of robust genetic markers that can be used to identify and evaluate the state of prostate cancer lineage plasticity. At the same time, these studies mainly rely on bulk transcriptome sequencing technology, so it is impossible to identify lineage plasticity-related cell types at single-cell resolution. Finally, the impact of such cell subpopulations on prostate cancer progression and their potential application value are still unknown. Summary of the invention
[0005] In view of this, the purpose of the present invention is to provide a new type of cell related to prostate cancer lineage plasticity and its identification method and application. Based on this type of cell subpopulation, the prediction of malignant progression and prognosis of prostate cancer can be achieved.
[0006] In order to achieve the above technical objectives, the technical solution adopted by the present invention is:
[0007] The present invention provides a method for identifying novel cells associated with prostate cancer lineage plasticity, comprising:
[0008] 1) Based on the PCaProfiler bulk RNA-seq cohort, WGCNA analysis was performed and combined with the NEPAL model to construct the lineage plasticity-related gene signature LPSig of prostate cancer. The cohort included human prostate cancer tissues of non-tumor prostate, primary prostate cancer, castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC);
[0009] 2) Generate a single-cell transcriptome profile based on a published human prostate cancer dataset, and use LPSig for AUCell enrichment analysis to show significant signals in epithelial cells. The samples of the single-cell transcriptome profile include normal prostate (N), non-tumor tissue adjacent sites (Adj), primary prostate cancer (Pri), castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer (CRPC / Met);
[0010] 3) Re-clustering analysis of epithelial cells further identified five major epithelial cell types, including basal cells, hillock cells, club cells, luminal cells, and neuroendocrine cells (LPCs), and screened out new cells with the highest LPSig score that were different from neuroendocrine cells.
[0011] Furthermore, the novel cells represent a lineage plasticity-associated malignant subpopulation that exhibits low AR activity, enhanced stem cell properties, and increased lineage plasticity-associated signals.
[0012] The present invention also provides a novel cell related to prostate cancer lineage plasticity, which is obtained by the above identification method.
[0013] The present invention further provides specific gene markers of the novel cells, including HMMR, EZH2 and AURKA.
[0014] The present invention further provides the use of the novel cell or specific gene marker in preparing a reagent for predicting the malignant progression and prognosis of prostate cancer.
[0015] Furthermore, increased activity of gene markers of the novel cells is significantly correlated with biochemical recurrence (BCR) in patients with hormone-sensitive prostate cancer and poor overall survival (OS) in patients with advanced prostate cancer.
[0016] Furthermore, the expression of HMMR gradually increases with the progression of prostate cancer and is particularly highly expressed in advanced prostate cancer.
[0017] Furthermore, HMMR expression is significantly associated with prostate cancer progression and poor prognosis.
[0018] The beneficial effects of the present invention are:
[0019] The present invention discovered and verified a never-before-described prostate cancer epithelial cell type LPCs that is highly associated with lineage plasticity, and further proposed an identification method for LPCs and its application, providing a new direction for the research of prostate cancer biomarkers and new possibilities for personalized and precise treatment of prostate cancer patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Technical roadmap of assays and experimental protocols for the discovery (A) and validation (B) of a prostate cancer lineage plasticity-associated gene signature (LPSig) and lineage plasticity-like epithelial cells (LPCs);
[0021] Figure 2 WGCNA analysis based on PCaProfiler, a large human prostate cancer bulk transcriptome sequencing dataset. A: Principal component analysis based on the PCaProfiler dataset (left), different colors represent different prostate cancer pathological stages; trajectory inference analysis of prostate cancer evolution (right), continuous coloring represents the differentiation state of different prostate cancer samples (i.e., pseudo-time score); B: Network topology analysis with different soft thresholds, the left figure shows the effect of soft threshold on the scale-free topological fit index; the right figure shows the effect of soft threshold on average connectivity; C: Heat map shows the Pearson correlation coefficient between different gene co-expression modules and lineage plasticity-related features; D: Univariate Cox regression analysis of different gene modules based on the TCGAPRAD (n=499) dataset or SU2CCRPC / Met (n=106) dataset and the patients' BCR or OS prognostic information;
[0022] Figure 3 To identify lineage plasticity-related cell subpopulations using the LPSig signature gene set, A: UMAP plot shows a large prostate cancer scRNA-seq map; B: Bubble plot shows representative markers for each cell subpopulation; C: Heat map shows the distribution of LPCSig enrichment scores in each prostate cancer subpopulation;
[0023] Figure 4A rare subpopulation of LPCs was identified in the scRNA-seq map of prostate cancer epithelial cells. A: UMAP map shows the scRNA-seq map of prostate cancer epithelial cells; B: Bubble map shows the mapping relationship between the epithelial cell subpopulations identified in this application and different prostate cancer epithelial cell subpopulations that have been published; C: UMAP map shows the clustering analysis results at different resolutions; D: Heat map shows the distribution of LPCSig enrichment scores in various subpopulations of prostate cancer epithelial cells; E: Violin plot shows the expression levels of representative gene markers related to lumen, proliferation, tumor stemness and lineage plasticity, and NE in different epithelial cell subpopulations; F: Violin plot shows the enrichment activity of AR signaling, stemness and NEPC risk model in different epithelial cell subpopulations; G: Heat map shows the copy number variation of malignant epithelial cells and non-malignant cells; H: Percentage bar graph shows the proportion of malignant epithelial cells to non-malignant epithelial cells in different prostate cancer epithelial cell subpopulations;
[0024] Figure 5 LPCs are associated with malignant progression and poor prognosis of prostate cancer. A: The heat map shows the enrichment preference of different epithelial cell subpopulations in the prostate cancer tumor microenvironment at different stages of prostate cancer progression, and the Ro / e algorithm is used for tissue enrichment preference analysis; B: The combined graph shows the infiltration abundance of LPCs cells in each patient (left) and at different stages of prostate cancer progression (right); C: The box plot shows the infiltration level of LPCs in different Gleason score groups in the TCGA-PRAD transcriptome dataset. Based on the prostate cancer scRNA-seq epithelial cell atlas and the TCGA-PRAD transcriptome dataset, the CIBERSORTx algorithm is used to predict the abundance of LPCs subpopulations; D: The forest plot shows the association between the abundance of LPCs and the biochemical recurrence (BCR) or overall survival (OS) of prostate cancer patients; E: Patients were grouped according to the abundance of LPCs for Kaplan-Meier survival analysis, and the survival curves showed the BCR or OS prognostic outcomes of different prostate cancer patient groups;
[0025] Figure 6HMMR is a representative cell surface marker of LPCs. A: Each scattered point represents a cell surface marker of LPCs, and the differentially expressed genes are sorted and displayed according to the Log2FC value; B and C: Violin plots show the expression levels of HMMR in different cell subsets in the prostate cancer scRNA-seq meta-atlas and EurUrol.Cheng.2022 single-cell datasets; D: The bubble plot shows the correlation between the expression level of HMMR and the degree of infiltration of LPCs in multiple prostate cancer Bulk datasets; E: Representative mIHC images of HMMR (green), CHGA (red), AR (pink) and DAPI (blue) in prostate cancer adjacent tissues, tumor samples of different Gleason grades, and CRPC samples; F: The scatter plot compares the AR expression levels of HMMR-positive and HMMR-negative tumor cells in different prostate cancer subtypes; G: The combined figure shows the representative H&E staining results of the prostate cancer spatial transcriptome dataset GSE230282, the AR signal activity score, and the spatial distribution pattern of HMMR expression;
[0026] Figure 7 The abnormal expression of HMMR is associated with the malignant progression and poor prognosis of prostate cancer. A: The expression level of HMMR in different prostate cancer subtypes in multiple human prostate cancer bulk transcriptome datasets; B: The combined graph shows the expression level of HMMR in wild-type LNCaP cells and LNCaP cells with double deletion of TP53 / RB1 genes, as well as the expression level in transgenic mice of different subtypes. C: Prostate cancer transgenic mice were grouped according to the expression level of HMMR for Kaplan-Meier survival analysis, and the survival curves showed the prognosis and survival outcomes of mice in different groups; D: The forest plot shows the association between the expression level of HMMR and the biochemical recurrence or overall survival rate of prostate cancer patients. DETAILED DESCRIPTION
[0027] In order to explain the present invention more clearly, the present invention is further described in detail below in conjunction with embodiments and with reference to the accompanying drawings. It should be understood by those skilled in the art that the content described below is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.
[0028] Example
[0029] Combination Figure 1 The present invention provides a novel method for identifying cell types associated with prostate cancer lineage plasticity, which mainly comprises:
[0030] 1. First, a comprehensive multicenter bulk RNA-seq cohort analysis was performed using weighted correlation network analysis (WGCNA), which included 1223 human prostate cancer tissues ranging from non-tumor prostate, primary prostate cancer, castration-resistant prostate cancer (CRPC) to neuroendocrine prostate cancer (NEPC). Figure 2 ). Subsequently, we identified 24 gene modules, each represented by a different color, among which the pink and tan modules were associated with tumor lineage plasticity and were associated with poor prognosis. Combining the NEPAL model further showed that the genes in these two gene modules were closely related to prostate cancer progression and lineage plasticity.
[0031] 2. Single-cell resolution accurate identification and in-depth understanding of lineage plasticity-related cells during prostate cancer progression are still lacking. To fill this gap, we generated a comprehensive single-cell transcriptome map from 10 published human prostate cancer datasets, including 222,529 individual cells, covering 93 samples of normal prostate (N), non-tumor adjacent sites (Adj), primary prostate cancer (Pri), castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer (CRPC / Met). AUCell enrichment analysis using LPSig showed significant signals in epithelial cells ( Figure 3 ). Reclustering analysis of 89,055 epithelial cells further identified five major epithelial cell types, including basal cells (Basal), hillock cells (Hillock), club cells (Club), luminal cells (Luminal), and neuroendocrine cells (LPCs). A smaller population of epithelial cells (1.29%) was found at a higher clustering resolution, with the highest LPSig score and different from neuroendocrine cells, which we call lineage plasticity-associated epithelial cells (LPCs) ( Figure 4 ). Differential expression analysis further showed that LPCs expressed classic epithelial cell markers and also shared markers associated with stem cell properties, proliferation, and lineage plasticity with neuroendocrine cells. In addition, GSEA analysis showed that LPCs shared many activation pathways associated with lineage plasticity and malignant development of prostate cancer with neuroendocrine cells. At the same time, CNV analysis and cluster analysis showed that LPCs and neuroendocrine cells had a high malignancy rate. These results indicate that LPCs represent a class of malignant subpopulations associated with lineage plasticity, showing low AR activity, enhanced stem cell properties, and increased lineage plasticity-related signals.
[0032] 3. Through our comprehensive human prostate cancer single-cell RNA sequencing atlas, we observed that LPCs were significantly enriched in tumor tissues (especially in advanced prostate cancer). Despite their limited abundance, LPCs were detected in almost every tumor sample, especially in castration-resistant prostate cancer tissues ( Figure 5 ). In addition, we found that increased gene signature activity in LPCs was significantly associated with biochemical recurrence (BCR) in hormone-sensitive prostate cancer patients and poor overall survival (OS) in patients with advanced prostate cancer.
[0033] 4. We further identified cell surface markers specifically expressed in LPCs, and found that HMMR ranked first. Further analysis revealed the specific expression of HMMR in LPCs ( Figure 6 ), indicating that HMMR is a representative cell surface marker of LPCs.
[0034] 5. In addition, the expression of HMMR gradually increases with the progression of prostate cancer, especially in advanced prostate cancer ( Figure 7 ). At the same time, HMMR expression is significantly associated with prostate cancer progression and poor prognosis. In summary, our study provides specific gene markers for accurate identification of LPC, including HMMR, EZH2, and AURKA ( Figure 4 E).
[0035] Obviously, the above embodiments of the present invention are merely examples to more clearly illustrate the present invention, and are not limitations on the implementation methods of the present invention. For ordinary technicians in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is impossible to list all the implementation methods here. All obvious changes or modifications derived from the technical solution of the present invention are still within the protection scope of the present invention.
Claims
1. A method for identifying novel cells associated with prostate cancer lineage plasticity, comprising: 1) Perform WGCNA analysis based on PCaProfiler bulk RNA-seq cohorts and construct a lineage plasticity-related gene signature LPSig for prostate cancer in combination with the NEPAL model. The cohort includes human prostate cancer tissues of non-tumor prostate, primary prostate cancer, castration-resistant prostate cancer, and neuroendocrine prostate cancer. 2) Generate a single-cell transcriptome map based on a published human prostate cancer dataset, and use LPSig for AUCell enrichment analysis to show significant signals in epithelial cells. The samples of the single-cell transcriptome map include normal prostate, adjacent sites of non-tumor tissue, primary prostate cancer, castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer; 3) Re-clustering analysis of epithelial cells further identified five major epithelial cell types, including basal cells, hillock cells, club cells, luminal cells, and neuroendocrine cells, and screened out new cells with the highest LPSig scores that were different from neuroendocrine cells.
2. The identification method according to claim 1, characterized in that: The novel cells represent a lineage plasticity-associated malignant subpopulation that exhibits low AR activity, enhanced stem cell properties, and increased lineage plasticity-associated signals.
3. A new type of cell associated with prostate cancer lineage plasticity, obtained by the identification method described in claim 1.
4. The specific gene markers of the novel cells according to claim 3, comprising HMMR, EZH2 and AURKA.
5. Use of the novel cell according to claim 3 or the specific gene marker according to claim 4 in the preparation of a reagent for predicting the malignant progression and prognosis of prostate cancer.
6. The use according to claim 5, characterized in that: Increased activity of the gene markers of the novel cells was significantly associated with biochemical recurrence in patients with hormone-sensitive prostate cancer and poor overall survival in patients with advanced prostate cancer.
7. The use according to claim 5, characterized in that: The expression of HMMR gradually increases with the progression of prostate cancer and is particularly highly expressed in advanced prostate cancer.
8. The use according to claim 5, characterized in that: The expression of HMMR is significantly associated with prostate cancer progression and poor prognosis.
Citation Information
Patent Citations
Prognostic tumor biomarkers
US20170298443A1
RRM2 signature genes as prognostic markers in prostate cancer patients
WO2020214718A1
